the Health Care Satellite Account, which promises to be an ongoing source of spending by medical condition, without double counting, for the civilian noninstitutionalized population. 2, 3 Estimates of health spending by medical condition for the entire US population, without double counting and benchmarked to the NHEA, were first developed in a 2009 study published in Health Affairs that covered the period 1996-2005. 4 This article updates those estimates through 2013, using similar data and methods. The inclusion of institutionalized populations has a significant impact on total spending and brings mental disorders to the top of the list of medical conditions with the highest estimated spending: $201 billion in 2013 (Exhibit 1).
Exhibit 1
Ten medical conditions with the highest estimated spending in 2013 Billions of dollars
Civilian noninstitutionalized Institutionalized and active-duty military

Study Data And Methods
Details about the data and methods are provided in online Appendix Exhibits A1 and A2. 5 In brief, NHEA service-category spending was adjusted (for example, shifting a portion of hospital spending to nursing home spending) to be consistent with other data sources. It was then apportioned across the following population segments: civilian noninstitutionalized, nursing home residents, long-term patients in psychiatric hospitals, prisoners, and members of the military on active duty. Three NHEA service categories (durable medical equipment, nondurable medical products, and other personal health care) were eliminated from consideration because of a lack of data suitable for allocating spending to medical conditions. For the remaining categories, which account for about 89 percent of spending, the allocation of spending to medical conditions was done separately for each population segment, with methods that eliminated double counting.
For the civilian noninstitutionalized population, which accounted for about 82 percent of spending, MEPS data were used to allocate spending across medical conditions for each included service category. Nursing home residents accounted for about 15 percent of spending, and the National Nursing Home Survey 6 was the primary data source for allocating their spending across medical conditions. The remaining population segments accounted for about 3 percent of health spending, and data and methods were identified, case by case, to allocate their spending to medical conditions (for specifics, see Appendix Exhibit A2, pages 12, 15, and 16).
5
Medical conditions were based on the 260 categories defined in the AHRQ Clinical Classifications Software and the ARHQ mapping architecture. Unless otherwise noted, AHRQ grouping schemes were used to create a smaller number of aggregate conditions. 7 MEPS assigns medical conditions to health care events based on survey self-reports and is known to undercount some high-cost cases, which results in potential errors and biases in that assignment. 8 MEPS survey methods were changed in 2007, which required adjustments that caused estimates presented here to differ from those in the 2009 study. 4 
Study Results
Ten Conditions With The Highest Estimated Spending In 2013 The top ten medical conditions in terms of estimated spending in 2013 are shown in Exhibit 1. The category of mental disorders tops the list by a substantial margin, at $201 billion-of which more than 40 percent is spending for institutionalized populations. Next are heart conditions and trauma, with spending at $147 billion and $143 billion, respectively. Cancer is fourth at $122 billion, and pulmonary conditions round out the top five at $95 billion.
The top five conditions in the AHRQ list of 2013 spending are trauma, heart conditions, mental disorders, cancer, and osteoarthritis. 1 The difference in rankings is primarily because AHRQ spending is limited to the civilian noninstitutionalized population, while this study included institutionalized people and members of the military on active duty.
Ten Conditions With The Fastest Spending Growth, 1996-2013 Personal health spending grew at an average annual rate of 5.9 percent between 1996 and 2013, while gross domestic product (GDP) grew by 4.3 percent (Exhibit 2). The difference between these two rates is commonly referred to as the "excess growth rate." In dollar terms, excess growth was $472 billion, in the sense that if health spending had grown at the same rate as the GDP between 1996 and 2013, health spending would have been $472 billion lower in 2013 than it actually was. (All dollar amounts mentioned are in nominal dollars-that is, not adjusted for inflation.)
Diseases related to the gallbladder, pancreas, and liver topped the list of the ten fastestgrowing conditions (Exhibit 2). The top four conditions grew by 10 percent annually, or nearly 6 percentage points faster than the GDP. Together they contributed $101 billion to excess growth, which is more than one-fifth of the $472 billion total. Growth in the next six fastest-growing conditions was 6-9 percent and contributed $160 billion to excess growth, about one-third of the total. Together, these ten fastest-growing conditions accounted for more than half of all excess spending growth.
Spending on mental disorders had a 5.6 percent growth rate and was not among the top ten. But because it is such a large category, it contributed the most in terms of excess dollars spent: $38 billion (data not shown). Another large category was heart conditions, which grew at only 2 percent. Spending on this category actually reduced excess growth by $70 billion, in the sense that it was $70 billion lower in 2013 than if it had grown at the same rate as the GDP.
Ten Conditions With The Greatest Slowdown After The Managed Care Backlash The history of health spending since 1996 includes the tail end of the managed care era (1996-99), when spending grew at an average annual rate of 5.8 percent; the years of managed care "backlash" The health spending slowdown that followed the managed care backlash has been of great interest to health economists. 2, 10 The contribution of medical conditions to this slowdown is examined here by comparing growth rates during the backlash period to those in later years.
Hyperlipidemia (high cholesterol) led the list of ten medical conditions with the greatest spending slowdown for the period (Exhibit 3). The average annual rate of spending growth for hyperlipidemia was 24 percent during the backlash period but only 2 percent thereafter-a drop of 22 percentage points. Next was upper gastrointestinal conditions, with a decline of 14 percentage points. Cancer and heart conditions were also in the top ten medical conditions with the greatest slowdown, with declines of 5 percentage points and 4 percentage points, respectively.
Spending By Diagnostic Categories And Selected Medical Conditions Among the major diagnostic categories, the circulatory system accounted for 14 percent of total expenditures in 2013 (Exhibit 4). The next-largest category was conditions  10  12  25  34  48 10  2  Neoplasms  58  61  85  122  129  5  6  Cancers  54  55  79  114  122  5  6  Respiratory system  60  71  85  106  147  5  7  Pulmonary conditions  35  44  55  68  95  6  4  COPD  11  11  14  19  30  6  1  Asthma  6  7  12  15  19  7  1  Pneumonia  16  17  17  24  33  4  2  Nervous system  50  56  78  101  125  6  6  Eye problems  15  15  22  26  32  4  1  Genitourinary system  32  38  61  77  101  7  5  Kidney disease  12  14  27  34  54  9  3  Endocrine system  26  32  48  74  101  8  5  Diabetes  14  17  26  43  62  9  3  Other categories   d   82  99  136  183  260  7  12  Normal birth  26  29  37  55  67  6  3  Screening, prevention, and exams  45  57  80  103  146  7  7  General exam  28  37  56  77  108  8  5  Dental  46  57  75  96  109  5 hypertension was offset by slow growth in spending on heart and cerebrovascular diseases. The fastest growth was seen in the digestive, endocrine, and musculoskeletal diagnostic categories, which had rates of growth of 8-9 percent.
Discussion
In 1996 the most costly medical condition, by far, was heart conditions, at $105 billion, with mental disorders a distant second at $79 billion. They had equal spending in 2004 ($131 billion each; data not shown), and by 2013 spending on mental disorders had moved far ahead-reaching $201 billion versus $147 billion spent on heart conditions. The story is not so much about rapid growth in spending on mental disorders, because the category's 5.6 percent average annual growth rate was about average for all personal health spending. Instead, what stands out is the 2 percent growth in spending on heart conditions over this period, which was more than 2 percentage points slower than GDP growth. Had national health expenditures (NHE) grown at the same rate as spending on heart conditions did, the NHE share of the GDP (13 percent in 1996) would have fallen to 9 percent in 2013 instead of increasing to 17 percent (author's calculations).
Nearly all of the ten fastest-growing medical conditions in terms of spending are associated with obesity. However, most of the spending growth rates are far too high to be fully explained by obesity-induced increases in disease prevalence. A more important factor appears to be the introduction of expensive new treatments that reached increasingly larger segments of the affected population over time, causing treated prevalence to rise much faster than the prevalence of disease. 11 A prime example is the introduction of Lipitor, a breakthrough treatment for hyperlipidemia that was introduced in 1996. Between 2000 and 2012 the number of people being treated for hyperlipidemia roughly doubled, despite only a modest increase in actual prevalence. 12 For most of the conditions with the greatest slowdown in spending growth after the managed care backlash, the major contributing factor was very high growth rates in the backlash period (2000-03)-not very low growth rates after that. For example, the category of upper gastrointestinal conditions had a 21 percent growth rate in the backlash period, followed by a 7 percent growth rate thereafter (Exhibit 3). Thus, to understand the causes for the slowdown, it would be useful to focus first on why the rates were so high during the backlash and then on why those high rates did not persist.
In the case of hyperlipidemia, initial high growth was attributable to the rapid diffusion of a breakthrough prescription drug, and the subsequent slowdown was due to a leveling off in diffusion of the drug, followed by a shift to lower-cost generic drugs after the patent on Lipitor expired. Spending on hyperlipidemia actually declined from $33 billion in 2007 to $27 billion in 2013 (Exhibit 4). It would be useful to flesh out a narrative for each of the remaining conditions on this list to identify additional overarching themes behind the slowdown.
Conclusion
One key finding of this study is the degree to which spending on mental disorders in 2013 exceeded that on all other medical conditions, including heart conditions, trauma, and cancer. Spending on mental disorders tends to be underestimated in other sources because institutionalized populations are excluded.
A second key finding is the continuing low rate of growth in spending on heart conditions and cerebrovascular disease. Most of the fastestgrowing medical conditions, in terms of spending, are associated with obesity, yet heart conditions and cerebrovascular disease-which are also associated with obesity-have exhibited very low spending growth. Age-adjusted death rates for these two conditions have been declining, and research suggests the importance of reductions in smoking, other lifestyle improvements, better control of risk factors such as hypertension and hyperlipidemia, and improvements in treatment. 13 A look ahead suggests that reductions in deaths from heart conditions and cerebrovascular disease are likely to drive spending on mental disorders even higher, as more people survive to older ages-when mental disorders, such as dementia, become more prevalent. ▪ 
